deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT01189760

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Sponsor: Allergan

Conditions Crow's Feet Lines Facial Rhytides Glabellar Lines
Interventions normal saline onabotulinumtoxinA 24 U onabotulinumtoxinA 44 U
Updated 9 times since 2017 Last updated: Apr 3, 2019 Started: Sep 1, 2010 Primary completion: Mar 1, 2011 Completion: Sep 1, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01189760, this PHASE3 trial focuses on Crow's Feet Lines and Facial Rhytides and remains completed. Sponsored by Allergan, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~May 2019 · 11 months · monthly snapshotCompleted~May 2019 – ~Jan 2021 · 20 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE3

▶ Show 4 earlier versions

  1. May 2019 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jun 2018 — May 2019 [monthly]

    Completed PHASE3

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Allergan
Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations